Knowledge is power when living with IBD.
Get access to the web’s leading IBD news & insights for as little as 16¢/day.Already a subscriber? Sign in here
Promising Phase 3 Trial Results for Ulcerative Colitis Therapy Xeljanz Announced by Pfizer
Pfizer has just announced top-line results from OCTAVE Sustain, the third Phase 3 study investigating Xeljanz (tofacitinib citrate) in patients with moderate-to-severe active ulcerative colitis (UC). The OCTAVE Clinical Development Program includes three studies – OCTAVE Induction 1, OCTAVE Induction 2 and OCTAVE Sustain, in addition to a long-term extension trial, OCTAVE Open. Phase 3